Navigation Links
Stem cells show promise for treating Huntington's disease
Date:9/25/2007

Paying close attention to how a canary learns a new song has helped scientists open a new avenue of research against Huntingtons disease a fatal disorder for which there is currently no cure or even a treatment to slow the disease.

In a paper published Sept. 20 in the Journal of Clinical Investigation, scientists at the University of Rochester Medical Center have shown how stem-cell therapy might someday be used to treat the disease. The team used gene therapy to guide the development of endogenous stem cells in the brains of mice affected by a form of Huntingtons. The mice that were treated lived significantly longer, were healthier, and had many more new, viable brain cells than their counterparts that did not receive the treatment.

While its too early to predict whether such a treatment might work in people, it does offer a new approach in the fight against Huntingtons, says neurologist Steven Goldman, M.D., Ph.D., the lead author of the study. The defective gene that causes the disease has been known for more than a decade, but that knowledge hasnt yet translated to better care for patients.

There isnt much out there right now for patients who suffer from this utterly devastating disease, said Goldman, who is at the forefront developing new techniques to try to bring stem-cell therapy to the bedside of patients. While the promise of stem cells is broadly discussed for many diseases, its actually conditions like Huntingtons where a very specific type of brain cell in a particular region of the brain is vulnerable that are most likely to benefit from stem-cell-based therapy.

The lead authors of the latest paper are Abdellatif Benraiss, Ph.D., research assistant professor at the University, and former post-doctoral associate Sung-Rae Cho, Ph.D., now at Yonsei University in South Korea.

The latest results have their roots in research Goldman did more than 20 years ago as a graduate student at Rockefeller University. In basic neuroscience studies, Goldman was investigating how canaries learn new songs, and he found that every time a canary learns a new song, it creates new brain cells called neurons. His doctoral thesis in 1983 was the first report of neurogenesis the production of new brain cells in the adult brain, and opened the door to the possibility that the brain has a font of stem cells that could serve as the source for new cells.

The finding led to a career for Goldman, who has created ways to isolate stem cells. These techniques have allowed Goldmans group to discover the molecular signals that help determine what specific types of cells they become, and re-create those signals to direct the cells development. Benraiss has worked closely with Goldman for more than 10 years on the Huntingtons project.

The type of brain cell that allows a canary to learn a new song is the same cell type that dies in patients with Huntingtons disease, said Goldman, professor of Neurology, Neurosurgery, and Pediatrics, and chief of the Division of Cell and Gene Therapy. Once we worked out the molecular signals that control the development of these brain cells, the next logical step was to try to trigger their regeneration in Huntingtons disease.

Huntingtons is an inherited disorder that affects about 30,000 people in the U.S. A defective gene results in the death of vital brain cells known as medium spiny neurons, resulting in involuntary movements, problems with coordination, cognitive difficulties, and depression and irritability. The disease usually strikes in young to mid adulthood, in a patients 30s or 40s; there is currently no way to slow the progression of the disease, which is fatal.

Stem cells offer a potential pool to replace neurons lost in almost any disease, but first scientists must learn the extensive molecular signaling that shapes their development. The fate of a stem cell depends on scores of biochemical signals in the brain, a stem cell might become a dopamine-producing neuron, perhaps, or maybe a medium spiny neuron, cells that are destroyed by Parkinsons and Huntingtons diseases, respectively.

To do this work, Goldmans team set up a one-two molecular punch as a recipe for generating new medium spiny neurons, to replace those that had become defective in mice with the disease. The team used a cold virus known as adenovirus to carry extra copies of two genes into a region of the mouse brain, called the ventricular wall, that is home to stem cells. This area happens to be very close to the area of the brain, known as the neostriatum, which is affected by Huntingtons disease.

The team put in extra copies of a gene called Noggin, which helps stop stem cells from becoming another type of cell in the brain, an astrocyte. They also put in extra copies of the gene for BDNF (brain-derived neurotrophic factor), which helps stem cells become neurons. Basically, stem cells were bathed in a brew that had extra Noggin and BDNF to direct their development into medium spiny neurons.

The results in mice, which had a severe form of Huntingtons disease, were dramatic. The mice had several thousand newly formed medium spiny neurons in the neostriatum, compared to no new neurons in mice that werent treated, and the new neurons formed connections like medium spiny neurons normally do. The mice lived about 17 percent longer and were healthier, more active and more coordinated significantly longer than the untreated mice.

The experiment was designed to test the idea that scientists could generate new medium spiny neurons in an organism where those neurons had already become sick. Now that the capability has been demonstrated, Goldman is working on ways to extend the duration of the improvement. Ultimately he hopes to assess this potential approach to treatment in patients.

This offers a strategy to restore brain cells that have been lost due to disease. That could perhaps be coupled with other treatments currently under development, said Goldman. Many of those treatments are being studied at the University, which is home to a Huntingtons Disease Center of Excellence and is the base for the Huntington Study Group.


'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Blood Cells Capable of Regenerating Liver
2. White Cells Count Can Predict Heart Attack Death Risk
3. Action of nerve cells
4. Common Cold Found to Fight Cancer Cells
5. Integrin helps healing process in cells
6. Therapy for stopping the spread of cancer cells
7. Hydroxyurea derivatives kill colon cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Creating brain cells from bone marrow
10. A Chinese herb kills cancer cells
11. Immune cells halt round in space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Tampa, Fla (PRWEB) , ... January 17, 2017 , ... ... IT Excellence Award for Innovation of the Year. , Each year, Pink ... has taken an innovative approach to address a specific business problem or opportunity. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Market 2016-2020" report to their offering. ... The global artificial pancreas devices system ... 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
(Date:1/17/2017)... 17, 2017 The interventional radiology products market ... from USD 6.35 billion in 2016, at a CAGR ... of this market are rising incidence of chronic diseases, ... surgeries. The global interventional radiology products market ... On the basis of type, the stents segment is ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
Breaking Medicine Technology: